AbCellera Biologics Inc. (ABCL)

AbCellera Biologics Stock Forecast

Stock Price Forecast

According to 3 professional analysts, the 12-month price target for AbCellera Biologics stock ranges from a low of $5.00 to a high of $10. The average analyst price target of $8.33 forecasts a 160.31% increase in the stock price over the next year.

Price Target: $8.33 (+160.31%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$5.00	$8.33	$10	$10
Change	+56.25%	+160.31%	+212.50%	+212.50%

* Price targets were last updated on May 16, 2025.

Analyst Ratings

The average analyst rating for AbCellera Biologics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '25	Feb '25	Mar '25	Apr '25	May '25	Jun '25
Strong Buy	1	1	1	1	2	2
Buy	1	1	1	1	1	1
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	3	3	3	3	4	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Robyn Karnauskas Truist Securities	Truist Securities	Strong Buy Maintains $28 → $10	Strong Buy	Maintains	$28 → $10	+212.50%	May 16, 2025
Scott Schoenhaus Keybanc	Keybanc	Buy Maintains $4 → $5	Buy	Maintains	$4 → $5	+56.25%	Apr 16, 2025
Robert Wasserman Benchmark	Benchmark	Hold Reiterates n/a	Hold	Reiterates	n/a	n/a	Mar 3, 2025
Stephen Willey Stifel	Stifel	Strong Buy Maintains $12 → $10	Strong Buy	Maintains	$12 → $10	+212.50%	Feb 28, 2025
Scott Schoenhaus Keybanc	Keybanc	Buy Maintains $5 → $4	Buy	Maintains	$5 → $4	+25.00%	Jan 8, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

20.77M

Decreased by -27.95%

from 28.83M

Revenue Next Year

34.67M

Increased by 66.89%

from 20.77M

EPS This Year

-0.66

from -0.55

EPS Next Year

-0.66

from -0.66

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	233.16M	375.20M	485.42M	38.03M	28.83M	20.77M	34.67M	46.92M
Revenue Growth	1,907.88%	60.92%	29.38%	-92.17%	-24.17%	-27.95%	66.89%	35.33%
EPS	0.45	0.48	0.50	-0.51	-0.55	-0.66	-0.66	-0.73
EPS Growth	-	6.21%	4.17%	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	12	10	6

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	27.5M	60.9M	72.5M
Avg	20.8M	34.7M	46.9M
Low	15.7M	22.5M	30.2M

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	-4.6%	193.2%	109.0%
Avg	-28.0%	66.9%	35.3%
Low	-45.5%	8.5%	-12.9%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	-0.60	-0.41	-0.59
Avg	-0.66	-0.66	-0.73
Low	-0.74	-0.79	-0.81

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.